The report "Cell Analysis Market by Product & Service (Consumables, Instruments), Technique (Flow Cytometry, PCR, Microscopy), Process (Counting, Viability, Proliferation, Interaction, Single-cell Analysis), End User (Pharma, Biotech) - Global Forecast to 2028", is projected to reach USD 33.9 billion by 2028 from USD 20.2 billion in 2023, at a CAGR of 10.9% during the forecast period.
Browse 233 market data Tables and 39 Figures spread through 250 Pages and in-depth TOC on "Cell Analysis Market by Product & Service (Consumables, Instruments), Technique (Flow Cytometry, PCR, Microscopy), Process (Counting, Viability, Proliferation, Interaction, Single-cell Analysis), End User (Pharma, Biotech) - Global Forecast to 2028"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/cell-analysis-market-157543946.html
Rising preference for cell-based assays in drug discovery serves as one of the key driving factors of the cell analysis market. Pharmaceutical & biotechnology companies and CROs are replacing biochemical assays with cell-based assays for their lead identification and optimization processes in drug discovery. This is attributive to the several advantages over in vitro biochemical assays. They offer consistent tissue-specific responses in a biologically relevant microenvironment as opposed to biochemical assays.
The software segment is estimated to grow at the fastest pace through the forecast period
Based on product & service, the global cell analysis market is segmented into reagents & consumables, instruments, accessories, software, and services. The software segment is a lucrative space owing to the advancements across single-cell analysis and flow cytometry techniques. This has elevated the influx of emerging companies entering cell analysis industry. Emerging companies building innovative software solutions has contributed to the robust growth rate registered by this segment.
The flow cytometry technique segment accounted for the largest share in the cell analysis market in 2022
Based on technique, the global cell analysis market is segmented into flow cytometry, PCR, cell microarrays, microscopy, spectrophotometry, high-content screening, and other techniques. The flow cytometry segment accounted for the largest market share of in 2022. Significant demand for flow cytometry technique across single-cell analysis and other different analysis processes is set to propel the market growth. Through flow cytometry multiple characteristics of single-cell particles can be measured and analyzed making it a preferable cell analysis technique for fluid samples.
The hospitals & clinical testing laboratories segment is estimated to grow with highest CAGR during the forecast period of cell analysis market
On the basis of end users, the cell analysis market is segmented into pharmaceutical & biotechnology companies, hospitals & clinical testing laboratories, academic & research institutes, and other end users. The demand for cell analysis products is set to elevate across in-house diagnostic and research centers, in-house pathology centers, and reference laboratories; collectively contributing to the fastest growth rate of hospitals & clinical testing laboratories during the forecast period. The development of highly specialized and complex cell-based assays is expected to supplement this growth.
Asia Pacific has registered fastest growth rate during the forecast period in cell analysis market
The global cell analysis market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The Asia Pacific market is estimated to grow at the highest CAGR during the forecast period. Rapid increase in the pharmaceutical & biopharmaceutical industries coupled with affordable with cell analysis services are the key contributing factors to the regional growth.
The cell analysis market is fragmented in nature with prominent players operating in this market such as Danaher (US), Thermo Fisher Scientific (US), Becton, Dickinson and Company (US), General Electric (US), Merck KGaA (US), Agilent Technologies (US), Olympus Corporation (Japan), Miltenyi Biotec (US), Bio-Rad Laboratories (US), BioStatus Limited (UK), Fluidigm Corporation (US), NanoCellect Biomedical (US), Cell Biolabs (US), Creative Bioarray (US), Meiji Techno (US), Promega Corporation (US), PerkinElmer (US), Tecan Trading AG (Switzerland), CELLINK (US), QIAGEN (Germany), Corning Incorporated (US), 10x Genomics (US), and Illumina (US).
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441